180 related articles for article (PubMed ID: 34182476)
1. The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.
Hwang K; Lee JH; Kim SH; Go KO; Ji SY; Han JH; Kim CY
In Vivo; 2021; 35(4):2015-2023. PubMed ID: 34182476
[TBL] [Abstract][Full Text] [Related]
2. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
3. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
4. Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Zampieri LX; Sboarina M; Cacace A; Grasso D; Thabault L; Hamelin L; Vazeille T; Dumon E; Rossignol R; Frédérick R; Sonveaux E; Lefranc F; Sonveaux P
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769368
[TBL] [Abstract][Full Text] [Related]
5. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Hanna C; Kurian KM; Williams K; Watts C; Jackson A; Carruthers R; Strathdee K; Cruickshank G; Dunn L; Erridge S; Godfrey L; Jefferies S; McBain C; Sleigh R; McCormick A; Pittman M; Halford S; Chalmers AJ
Neuro Oncol; 2020 Dec; 22(12):1840-1850. PubMed ID: 32347934
[TBL] [Abstract][Full Text] [Related]
7. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
8. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
9. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
12. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
[TBL] [Abstract][Full Text] [Related]
15. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
17. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Valiakhmetova A; Gorelyshev S; Konovalov A; Trunin Y; Savateev A; Kram DE; Severson E; Hemmerich A; Edgerly C; Duncan D; Britt N; Huang RSP; Elvin J; Miller V; Ross JS; Gay L; McCorkle J; Rankin A; Erlich RL; Chudnovsky Y; Ramkissoon SH
Oncologist; 2020 Feb; 25(2):e198-e202. PubMed ID: 32043779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
